Aegera Therapeutics Inc., of Montreal, said it received U.S. Patent No. 6,171,821. It covers inhibitors of apoptosis.
American Biogenetic Sciences Inc., of Copiague, N.Y., said it received U.S. Patent No. 6,187,593. It covers an invention useful for the treatment of malignant and benign tumors containing fibrin.
Ariad Pharmaceuticals Inc., of Cambridge, Mass., said it received U.S. Patent No. 6,187,757. It covers an approach to determining the function of genes and the proteins they encode.
Biochem Pharma Inc., of Laval, Quebec, said it received U.S. Patent No. 6,180,639. It covers pharmaceutical compositions comprising lamivudine in combination with other antiviral agents as well as methods of treating HIV infection using lamivudine and other antiviral agents.
Corixa Corp., of Seattle, said it received U.S. Patent No. 6,171,590. It covers certain compositions and methods for inducing an immune response using chemokine receptor peptides.
Endorex Corp., of Lake Forest, Ill., said it received U.S. Patent No. 6,187,335. It covers new lipids useful in delivery of drugs to the intestinal tract and other mucosal surfaces.
ETEX Corp., of Cambridge, Mass. said it received three U.S. patents covering a method of seeding the company's proprietary calcium phosphate material with cartilage, bone and other tissue-forming or tissue-degrading cells. Further information was unavailable.
Immunomedics Inc., of Morris Plains, N.J., said it received U.S. Patent No. 6,183,744. It covers methods for the therapy of B-cell lymphomas with anti-CD22 antibodies. The company also said it received U.S. Patent Nos. 6,187,287, which covers humanized and chimerized forms of its CD22 antibody under development as a non-Hodgkin's lymphoma treatment, and 6,187,284, which covers the fluorination of proteins and peptides for F-18 positron emission tomography.
InfiMed Therapeutics Inc., of Cambridge, Mass., said it received U.S. Patent No. 6,153,211. It covers company technology for incorporating peptides and proteins into "fishnet-like" hydrogel polymers that form into small microspheres that can be injected subcutaneously, intramuscularly or inhaled into the lungs to provide a depot for sustained systemic delivery of protein and peptide drugs for one week to several months.
Keryx Biopharmaceuticals Inc., of Jerusalem, said it received U.S. Patent No. 6,080,732. It covers use of KRX-101 (sulodexide) in treatment of diabetic retinopathy.
Kosan Biosciences Inc., of Hayward, Calif., said it received U.S. Patent Nos. 6,066,721 and 6,080,555. The patents cover methods, recombinant cells and DNA vectors for producing novel polyketides with Kosan's "ChemoBiosynthesis." Kosan also said it received U.S. Patent Nos. 6,177,262; 6,150,153; 6,117,659 and 6,090,601. They cover polyketide gene alteration and production.
Maxygen Inc., of Redwood City, Calif., said it received U.S. Patent No. 6,177,263. It covers in vitro methods for template-based gene recombination to produce chimeric genes.
PlantGenix Inc., of Philadelphia, said it received U.S. Patent No. 6,166,290. It covers genetic technologies that facilitate the use of plants to produce pharmaceutical and chemical compounds, detoxify contaminated soils, enhance the nutritional value and health benefits of food and increase the resistance of plants to herbicides.